Pfizer Halts Production of Dobutamine and Dopamine Hospital Injections

The U.S. Food and Drug Administration’s medicines database on 27 Aug 2025 showed that Pfizer has discontinued manufacturing Dobutamine Hydrochloride Injection, 12.5 mg/1 mL. The notification ends production of a formulation widely supplied by the company for hospital use. The same FDA update lists a second action by Pfizer’s Hospira unit, which has stopped producing Dopamine Hydrochloride Injection in 5 % dextrose, 800 mg/500 mL plastic containers. Pfizer did not give a reason for either discontinuation in the FDA posting.